Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action

被引:74
作者
Sprenger, Till [1 ]
Viana, M. [2 ]
Tassorelli, C. [2 ,3 ]
机构
[1] DKD Helios Klin Wiesbaden, Dept Neurol, Aukammallee 33, D-65191 Wiesbaden, Germany
[2] IRCCS, Mondino Fdn, Headache Sci Ctr, I-27100 Pavia, Italy
[3] Univ Pavia, Dept Brain & Behav Sci, I-27100 Pavia, Italy
关键词
Migraine prevention; Mechanism of actions; Cortical spreading depression; beta blockers; Antiepileptic drugs; Antidepressants; Botulinumtoxin; TOXIN TYPE-A; CORTICAL SPREADING DEPRESSION; CHRONIC DAILY HEADACHE; PLACEBO-CONTROLLED PHASE; TENSION-TYPE HEADACHE; HIGH-DOSE RIBOFLAVIN; FACTOR-KAPPA-B; BOTULINUM-TOXIN; DOUBLE-BLIND; BETA-BLOCKERS;
D O I
10.1007/s13311-018-0621-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A relatively high number of different medications is currently used for migraine prevention in clinical practice. Although these compounds were initially developed for other indications and differ in their mechanisms of action, some general themes can be identified from the mechanisms at play. Efficacious preventive drugs seem to either suppress excitatory nervous signaling via sodium and/or calcium receptors, facilitate GABAergic inhibition, reduce neuronal sensitization, block cortical spreading depression and/or reduce circulating levels of CGRP. We here review such mechanisms for the different compounds.
引用
收藏
页码:313 / 323
页数:11
相关论文
共 144 条
[1]   MIGRAINE AND BETA-BLOCKADE - MODULATION OF SYMPATHETIC NEUROTRANSMISSION [J].
ABLAD, B ;
DAHLOF, C .
CEPHALALGIA, 1986, 6 :7-13
[2]   Effectiveness of Petasites hybridus preparations in the prophylaxis of migraine:: A systematic review [J].
Agosti, R. ;
Duke, R. K. ;
Chrubasik, J. E. ;
Chrubasik, S. .
PHYTOMEDICINE, 2006, 13 (9-10) :743-746
[3]   Angiotensin receptors in the nervous system [J].
Allen, AM ;
Moeller, I ;
Jenkins, TA ;
Zhuo, J ;
Aldred, GP ;
Chai, SY ;
Mendelsohn, FAO .
BRAIN RESEARCH BULLETIN, 1998, 47 (01) :17-28
[4]   Updates on the antinociceptive mechanism hypothesis of botulinum toxin A [J].
Aoki, K. Roger ;
Francis, Joseph .
PARKINSONISM & RELATED DISORDERS, 2011, 17 :S28-S33
[5]   Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A [J].
Aoki, KR .
NEUROTOXICOLOGY, 2005, 26 (05) :785-793
[6]  
Aoki KR, 2003, HEADACHE, V43, pS9
[7]   A neural circuit for circadian regulation of arousal [J].
Aston-Jones, G ;
Chen, S ;
Zhu, Y ;
Oshinsky, ML .
NATURE NEUROSCIENCE, 2001, 4 (07) :732-738
[8]  
Aurora SK, 2010, CEPHALALGIA, V30, P793, DOI 10.1177/0333102410364676
[9]   Botulinum toxin type A prophylactic treatment of episodic migraine: A randomized, double-blind, placebo-controlled exploratory study [J].
Aurora, Sheena K. ;
Gawel, Marek ;
Brandes, Jan L. ;
Pokta, Suriani ;
VanDenburgh, Amanda M. .
HEADACHE, 2007, 47 (04) :486-499
[10]   Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies [J].
Aurora, Sheena K. ;
Brin, Mitchell F. .
HEADACHE, 2017, 57 (01) :109-125